DocGo (NASDAQ:DCGO) PT Lowered to $9.00 at Canaccord Genuity Group

DocGo (NASDAQ:DCGO) had its price objective cut by Canaccord Genuity Group from $10.00 to $9.00 in a report issued on Thursday morning, Benzinga reports. They currently have a buy rating on the stock.

A number of other research firms also recently weighed in on DCGO. BTIG Research reduced their target price on shares of DocGo from $13.00 to $11.00 and set a buy rating on the stock in a report on Wednesday. Stifel Nicolaus reduced their target price on shares of DocGo from $11.00 to $8.00 and set a buy rating on the stock in a report on Wednesday. Cantor Fitzgerald reduced their target price on shares of DocGo from $13.00 to $11.00 and set an overweight rating on the stock in a report on Thursday, February 29th. Finally, Needham & Company LLC reduced their target price on shares of DocGo from $14.00 to $10.00 and set a buy rating on the stock in a report on Thursday, February 29th. Five analysts have rated the stock with a buy rating, Based on data from MarketBeat, DocGo has an average rating of Buy and a consensus price target of $10.83.

DocGo Stock Down 2.8 %

Shares of DCGO stock opened at $3.26 on Thursday. The stock has a market cap of $339.59 million, a P/E ratio of 46.57, a PEG ratio of 0.33 and a beta of 0.91. DocGo has a 52 week low of $2.78 and a 52 week high of $10.82. The company’s fifty day simple moving average is $3.73 and its two-hundred day simple moving average is $4.70.

DocGo (NASDAQ:DCGO) last posted its earnings results on Wednesday, February 28th. The company reported $0.06 earnings per share for the quarter, missing analysts’ consensus estimates of $0.13 by ($0.07). DocGo had a return on equity of 2.01% and a net margin of 1.10%. The business had revenue of $199.25 million during the quarter, compared to the consensus estimate of $195.48 million. On average, analysts anticipate that DocGo will post 0.35 EPS for the current fiscal year.

Insider Activity at DocGo

In other news, Director Michael J. Burdiek purchased 10,000 shares of the business’s stock in a transaction that occurred on Thursday, March 14th. The shares were bought at an average cost of $3.61 per share, for a total transaction of $36,100.00. Following the acquisition, the director now owns 571,595 shares of the company’s stock, valued at approximately $2,063,457.95. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 13.78% of the stock is currently owned by insiders.

Institutional Investors Weigh In On DocGo

Several large investors have recently added to or reduced their stakes in DCGO. AJOVista LLC purchased a new stake in DocGo in the 4th quarter valued at about $25,000. Federated Hermes Inc. purchased a new stake in shares of DocGo in the 3rd quarter worth approximately $29,000. Royal Bank of Canada lifted its position in shares of DocGo by 226.3% in the 1st quarter. Royal Bank of Canada now owns 3,263 shares of the company’s stock worth $30,000 after purchasing an additional 2,263 shares during the period. Tower Research Capital LLC TRC lifted its position in shares of DocGo by 145.6% in the 3rd quarter. Tower Research Capital LLC TRC now owns 5,908 shares of the company’s stock worth $31,000 after purchasing an additional 3,502 shares during the period. Finally, Wells Fargo & Company MN lifted its position in shares of DocGo by 320.1% in the 4th quarter. Wells Fargo & Company MN now owns 6,192 shares of the company’s stock worth $44,000 after purchasing an additional 4,718 shares during the period. 56.44% of the stock is owned by hedge funds and other institutional investors.

DocGo Company Profile

DocGo Inc provides mobile health and medical transportation services for various health care providers in the United States and the United Kingdom. The company's transportation services include emergency response services; and non-emergency transport services comprise ambulance and wheelchair transportation services.